4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 9, 2012, Pages 3235-3239

  Jimenez, Hermogenes N ^a   Liu, Kevin G ^a   Hong, Sang Phyo ^a   Reitman, Michael S ^a   Uberti, Michelle A ^a   Bacolod, Maria D ^a   Cajina, Manuel ^a   Nattini, Megan ^a   Sabio, Michael ^a   Doller, Darío ^a  

^a LUNDBECK RESEARCH USA   (United States)

Author keywords

Hit to lead; mGlu4 PAM; Parkinson's disease; Positive allosteric modulation; Structure activity relationships

Indexed keywords

4 (1 PHENYL 1H PYRAZOL 4 YL)QUINOLINE; GLUTAMIC ACID; METABOTROPIC RECEPTOR 4; METHYL GROUP; PYRAZOLE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; HUMAN; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ANIMALS; BRAIN; DRUG EVALUATION, PRECLINICAL; QUINOLINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859813221     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.03.032     Document Type: Article

References (30)

1. S.A. Factor, and W.J. Weiner Parkinson's Disease 2nd ed. 2008 Demos Medical Publishing New York
2. P.J. Conn, G. Battaglia, M.J. Marino, and F. Nicoletti Nat. Rev. Neurosci. 6 2005 787
3. C.W. Lindsley, C.M. Niswender, D.W. Engers, and C.R. Hopkins Curr. Top. Med. Chem. 9 2009 949
4. For a recent review see: S. Célanire, and B. Campo Expert Opin. Drug Disc. 7 2012 261
5. C.K. Jones, M. Bubser, A.D. Thompson, J.W. Dickerson, N. Turle-Lorenzo, M. Amalric, A.L. Blobaum, T.M. Bridges, R.D. Morrison, S. Jadhav, D.W. Engers, K. Italiano, J. Bode, J.S. Daniels, C.W. Lindsley, C.R. Hopkins, P.J. Conn, and C.M. Niswender J. Pharmacol. Exp. Ther. 340 2012 404
6. S.P. East, S. Bamford, M.G. Dietz, C. Eickmeier, A. Flegg, B. Ferger, M.J. Gemkow, R. Heilker, B. Hengerer, A. Kotey, P. Loke, G. Schänzle, H.D. Schubert, J. Scott, M. Whittaker, M. Williams, P. Zawadzki, and K. Gerlach Bioorg. Med. Chem. Lett. 20 2010 4901
7. C.K. Jones, D.W. Engers, A.D. Thompson, J.R. Field, A.L. Blobaum, S.R. Lindsley, Y. Zhou, R.D. Gogliotti, S. Jadhav, R. Zamorano, J. Bogenpohl, Y. Smith, R. Morrison, J.S. Daniels, C.D. Weaver, P.J. Conn, C.W. Lindsley, C.M. Niswender, and C.R. Hopkins J. Med. Chem. 54 2011 7639
8. R. Williams, K.A. Johnson, P.R. Gentry, C.M. Niswender, C.D. Weaver, P.J. Conn, C.W. Lindsley, and C.R. Hopkins Bioorg. Med. Chem. Lett. 19 2009 4967
9. R. Williams, C.M. Niswender, Q. Luo, U. Le, C.D. Weaver, P.J. Conn, C.W. Lindsley, and C.R. Hopkins Bioorg. Med. Chem. Lett. 19 2009 962
10. C.M. Niswender, K.A. Johnson, C.D. Weaver, K.J. Carrie, Z. Xiang, Q. Luo, A.L. Rodriguez, J.E. Marlo, T. Paulis, A.D. Thompson, E.L. Days, T. Nalywajko, C.A. Austin, M.B. Williams, J.E. Ayala, R. Williams, C.W. Lindsley, and P.J. Conn Mol. Pharmacol. 74 2008 1345
11. D.W. Engers, C.M. Niswender, C.D. Weaver, S. Jadhav, U.N. Menon, R. Zamorano, P.J. Conn, C.W. Lindsley, and C.R. Hopkins J. Med. Chem. 52 2009 4115
12. R. Williams, Y. Zhou, C.M. Niswender, Q. Luo, P.J. Conn, C.W. Lindsley, and C.R. Hopkins ACS Chem. Neurosci. 1 2010 411
13. S.G. Moyanova, F. Mastroiacovo, L.V. Kortenska, R.G. Mitreva, E. Fardone, I. Santolini, M. Sobrado, G. Battaglia, V. Bruno, F. Nicoletti, and R.T. Ngomba J. Cereb. Blood Flow Metab. 31 2011 1107
14. G. Besong, G. Battaglia, M. D'Onofrio, R. Di Marco, R.T. Ngomba, M. Stortom, M. Castiglione, K. Mangano, C.L. Busceti, F.R. Nicoletti, K. Bacon, M. Tusche, O. Valenti, P.J. Conn, V. Bruno, and F. Nicoletti J. Neurosci. 22 2002 5403
15. max (160 ± 20%) values of PHCCC were reproducible, and no normalization of tested mGlu4 PAMs was applied other than to the reference glutamate curve.
16. C.R. Hopkins, C.R. Lindsley, and C.M. Niswender Future Med. Chem. 1 2009 501
17. A.J. Robichaud, D.W. Engers, C.W. Lindsley, and C.R. Hopkins ACS Chem. Neurosci. 2 2011 433
18. Bolea, C.; Celanire, S. Preparation of novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors. Patent WO 2009010455, 2009.
19. Bolea, C.; Celanire, S. Preparation of heteroaryl dihydrothiazolo- indazoleamine derivatives and analogs as metabotropic glutamate receptors modulators. Patent WO 2010079238, 2010.
20. Bolea, C. Novel thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors and preparation. Patent WO 2010079239, [2010]
21. Bolea, C. Novel pyrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors and their preparation. Patent WO 2011010222, 2011.
22. Jones, P.; Tang, L.; Bolea, C.; Celanire, S.; Liverton, N. J. Tetrahydropyrazolo[3,4-b]thiazolo[4.5-d]azepine derivatives as mGluR4 modulators and their preparation and use for treatment and prevention of CNS disorders and mGluR4-mediated diseases. Patent WO 2012009001, 2012.
23. Bolea, C.; Celanire, S.; Boudou, C.; Tang, L.; Rocher, J.-P.; Liverton, N. J. 4-(1H-Pyrazol-4-yl)thiazol-2-amine derivatives as mGluR4 modulators and their preparation and use for treatment and prevention of CNS disorders and mGluR4-mediated diseases. Patent WO 2012009009, 2012.
24. Liverton, N. J.; Bolea, C.; Celanire, S.; Yunfu, L. Tricyclic fused thiazolopyrazole compounds as allosteric modulators of metabotropic glutamate receptors. Patent WO 2012008999, 2012.
25. Liverton, N. J.; Bolea, C.; Celanire, S.; Luo, Y. Tricyclic compounds as mGluR4 modulators and their preparation and use for treatment and prevention of mGluR4-mediated diseases. Patent WO 2012006760.
26. Conn, P. J.; Lindsley, C. W.; Hopkins, C. R.; Weaver, C. D.; Niswender, C. M.; Gogliotti, R. D.; Cheung, Y.-Y.; Salovich, J. M.; Engers, D. W. Heterocyclic sulfone metabotropic glutamate receptor subtype 4 allosteric potentiators and compositions, and methods of treating neurological dysfunction. Patent WO 2011143466, 2011.
27. Conn, P. J.; Lindsley, C. W.; Hopkins, C. R.; Weaver, C. D.; Niswender, C. M.; Engers, D. W. Benzisoxazoles and azabenzisoxazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. Patent WO 2011100614, 2011.
28. Conn, P. J.; Lindsley, C. W.; Hopkins, C. R.; Niswender, C. M.; Gogliotti, R. D.; Salovich, J. M.; Engers, D. W.; Cheung, Y.-Y. Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators and for treating neurological dysfunctions. Patent WO 2011100607, 2011.
29. East, S. P.; Gerlach, K. Expert Opin. Ther. Patents 2010, 20, 441.
30. S.P. Hong, K.G. Liu, G. Ma, M. Sabio, M.A. Uberti, M.D. Bacolod, J. Peterson, Z.Z. Zou, A.J. Robichaud, and D. Doller J. Med. Chem. 54 2011 5070